Watch Shane Smith's debrief from VICE's HBO Special, "Killing Cancer"Earlier today, the Food and Drug Administration announced the approval of Imlygic, a new drug that uses herpes to fight melanoma-related lesions that cannot be totally removed by surgery.According to the FDA's press release, the drug works something like this: Imlygic gets directly into a cancerous tumor, where a modified version of the Herpes Simplex virus then "replicates inside cancer cells and causes the cells to rupture and die."In its press release, the FDA explained that though the cancer-fighting herpes was shown to decrease the size of cancerous lesions with a higher efficacy rate than a placebo, it was by no means a panacea. It was not effective in fighting cancer that had spread to other parts of the body, and not shown to improve overall survivor rate.Follow Drew on Twitter.